<DOC>
	<DOCNO>NCT01952327</DOCNO>
	<brief_summary>This research study examine safety new , automated pump drainage fluid chest cavity cause cancer ( also know malignant pleural effusion , MPE ) . The purpose trial ass whether new pleurapump device safe effective management patient MPE . The study try identify kind problem may arise use device , often happen , severe occur .</brief_summary>
	<brief_title>Investigation Into Automated Drainage Recurrent Effusions From Pleural Space Thoracic Malignancy .</brief_title>
	<detailed_description />
	<mesh_term>Pleural Effusion</mesh_term>
	<criteria>1 . &gt; 18 year age 2 . Recurrent pleural effusion due malignancy Malignant pleural effusion define either Fluid context histocytologically confirm pleural malignancy , pleural fluid context histocytologically confirm malignancy elsewhere , clear cause effusion . 3 . 1 therapeutic procedure pleural fluid drainage prior enrolment . 4 . Written inform consent 5 . Ability comply study procedure ability operate device 6 . Expected survival 3 month device insertion 1 . Haemothorax 2 . Purulent pleural effusion 3 . Significant pleural fluid septation loculation thoracic ultrasound crosssectional image 4 . Obstructive uropathy bladder anomaly might contraindicate implantation device . 5 . Pregnant female female anticipate pregnancy study period . 6 . Patients currently enrol another interventional clinical study 7 . Concurrently implant Active Implantable Medical Device , include , limited cardiac pacemaker cardioverter defibrillator . 8 . Major comorbidity , opinion principal investigator , likely significantly decrease life expectancy , increase anaesthetic risk , lead device removal ( e.g . moderate severe congestive heart failure , significant valvular heart disease , persistent immunosuppression , etc . ) 9 . Other contraindication general anaesthesia 10 . Other contraindication procedure ( e.g . uncorrectable bleed diathesis , infection malignant involvement propose insertion site ) 11 . Significant renal impairment , determine principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>